Exicure joins hands with GPCR Therapeutics for growth in biotech

Stock Information for Exicure Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Exicure Inc.

Kuehn Law Encourages Investors of Exicure, Inc. to Contact Law Firm
CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech
CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes
Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes
Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results
Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.